Stanley Druckenmiller Holds Significant Stake in Natera Amid Strong Growth
Billionaire investor Stanley Druckenmiller holds approximately 16.6% of his $5.2 billion Duquesne Family Office portfolio in genomics company Natera (NTRA). The stock has surged roughly 80% since its year-to-date low on May 15, 2026. Druckenmiller first invested in Natera during Q3 of 2022 and continued to add shares through the second quarter of 2026. Recent financial results show strong performance: revenue rose 37.7% year-over-year to $752.8 million, with over a million tests processed in Q2—up 22.4%. The oncology segment drove much of this growth, particularly from Signatera, Natera's personalized blood test for detecting tumor DNA. Despite regulatory approvals and certifications across the U.S., Japan, and EU, concerns remain about valuation. At around 17 times trailing sales, some analysts view it as overpriced given its unprofitable status.
Tickers: $NTRA
Topics: genomics industry growth Natera (NTRA) portfolio strategy Stanley Druckenmiller